Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty Patients

Launched by JOHNNY K. LEE · Jun 9, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how effective a special type of pain relief called Liposomal Bupivacaine is when used in a specific anesthesia technique called an interscalene block for patients undergoing shoulder surgery. The goal is to see if this new treatment helps patients experience less pain, recover better, and use fewer opioid medications after their surgery compared to a standard treatment. The trial will include around 130 participants who will be randomly assigned to receive either the standard pain medication or the combination of Liposomal Bupivacaine and another local anesthetic.

To be eligible for this study, you need to be between 18 and 90 years old, weigh at least 60 kg (about 132 pounds), and be able to provide consent in English. The study is open to both men and women. If you join, you can expect to receive one of the two treatments and will be monitored for several days after your surgery to assess your pain levels and recovery. It’s important to note that certain medical conditions, allergies, or situations, like being pregnant or having severe kidney or liver disease, may prevent you from participating.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subject ages 18-90 years old
• • Male or Female subjects
• • Weight ≥ 60 kg.
• • Must be able to consent in English
• Exclusion Criteria:
• • Ages: \<18 and \>90
• • Weight \< 60 kg
• • Multiple surgeries during one hospital stay
• • Emergency surgery
• • Allergy or any contraindication to local anesthetics used in trial.
• • Pregnancy
• • Contraindicated for use of liposomal bupivacaine
• • Severe liver/kidney disease
• • Defined as a diagnosis of end-stage renal disease (ESRD) defined as being on dialysis
• • Subject who received another local anesthetic block prior to the interscalene block.
• • Unable to consent in English